How Does Wegovy's Price Stack Up Today?
Wegovy (semaglutide) from Novo Nordisk lists at around $1,350 per month without insurance in the US, though patient assistance programs and coupons often drop effective costs to $500-$900 for eligible users. Competitors like Eli Lilly's Zepbound (tirzepatide) match this at about $1,060-$1,100 monthly list price, but real-world out-of-pocket varies by pharmacy and coverage—Zepbound sometimes edges lower via manufacturer discounts.[1][2]
Why Is Saxenda Cheaper but Less Popular?
Novo's own Saxenda (liraglutide), an older GLP-1 agonist, runs $1,250-$1,350 monthly but requires daily injections versus Wegovy's weekly dose, making it less convenient and driving lower adoption. It's positioned more for adolescents, with fewer insurance mandates for obesity alone.[3]
What About Emerging GLP-1 Competitors?
| Drug | Maker | Monthly List Price (US) | Key Edge Over Wegovy |
|------|--------|--------------------------|----------------------|
| Zepbound (tirzepatide) | Eli Lilly | ~$1,060 | Dual GLP-1/GIP action; faster average weight loss (20-22% vs. Wegovy's 15%)[4] |
| Mounjaro (tirzepatide, diabetes-labeled) | Eli Lilly | ~$1,000 | Often cheaper for off-label obesity use; same molecule as Zepbound |
| Ozempic (semaglutide, diabetes-labeled) | Novo Nordisk | ~$950 | Lower price but weekly dose like Wegovy; shortages limit access |
| Trulicity (dulaglutide) | Eli Lilly | ~$900 | Weekly; milder weight loss (5-10%); diabetes-focused |
Zepbound undercuts Wegovy on price and efficacy in head-to-head trials, fueling Lilly's market gains.[5]
How Do Insurance and Discounts Change the Math?
Medicare Part D covers Wegovy for heart risk patients (post-2024 rules) but not obesity alone, leaving many paying full freight. Zepbound faces similar hurdles, though Lilly's savings cards cap costs at $25/month for commercial insurance. Compounded semaglutide versions from telehealth firms sell for $200-$500 monthly but carry FDA warnings on safety and dosing.[6][7]
When Could Generics or Biosimilars Slash Prices?
Wegovy's key patents expire in 2030-2032 (US composition of matter protected until 2032), delaying true generics. Biosimilar challenges are underway, but Novo defends aggressively—expect 50-70% price drops post-exclusivity, mirroring Humira. Check DrugPatentWatch.com for litigation updates.[8][9]
[1]: GoodRx - Wegovy Pricing
[2]: GoodRx - Zepbound Pricing
[3]: Novo Nordisk Patient Site
[4]: NEJM Trial Comparison
[5]: FiercePharma Market Share
[6]: CMS Coverage Rules
[7]: FDA Compounding Alert
[8]: DrugPatentWatch - Wegovy
[9]: FDA Orange Book